In their cutting-edge paper of 1986, Gotoh et al. [20] reported that NSE in urine may be a valuable marker for monitoring the effectiveness of therapy in patients with neuroblastoma, while later in the early 2000s, Wijnberger et al. [21] investigated the potential association of NSE in cord blood, amniotic fluid, and placental tissue with perinatal damage. Here, ENO2 is linked to neuroblastoma.